I'm thinking you are correct here. Whatever it is, the man isn't letting any grass grow under his feet. The company is moving along on multiple fronts. ;)
In Reply to 'John B'
I wonder if Leo is in India for this for Brilacidin:
•Ophthalmic infections: As disclosed in November (See press release dated November 4, 2013) 2013), the company has identified ocular infections, such as keratitis, as an area of unmet medical need and significant commercial potential, based on positive preclinical data supporting safety, antimicrobial efficacy, and prolonged residence time on the ocular surface with minimal systemic exposure. The Company has received proposals for the necessary formulation and will shortly select a manufacturer.